Sebastian Bio Pharma

www.sebastianbio.com

Contact:
Greta Garrido, CEO & Co-Founder
greta.garrido@sebastianbio.com
786-717-0995

Mission

To develop a first-in-kind therapeutic platform that enhances patient response to immune therapy–including PD-1 antibodies –by increasing tumor neoantigen content. This breakthrough aims to expand treatment access for 75-85% of cancer patients currently excluded from FDA-approved PD-1 therapies due to neoantigen-deficient tumors, addressing a critical benchmark in cancer immunotherapy.

Unmet Medical Need

- Colorectal cancer alone leaves >138 k patients every year without an effective PD-1 option because their tumors are neoantigen-negative.
- Similar neoantigen gaps exist across multiple solid tumors, representing a multi-billion-dollar population currently unaddressed by checkpoint inhibitors.

Solution: The PD-1REBOOT Platform

- iTAP – a tumor-specific Antibody-Oligonucleotide Conjugate (AOC) that induces shared neoantigens by targeting TAP, a central component of the antigen presentation machinery.
- iTAP combined with any approved PD-1 antibody to deliver synergistic, durable tumor rejection with no added systemic toxicity in pre-clinical models.
- Plug-and-play, tumor-agnostic, and first-in-class among neoantigen-inducing approaches.

Traction & IP

- Exclusive license from University of Miami; 2 patents pending.
- 4 peer-reviewed publications validating mechanism.
- Compelling efficacy and safety across >6 human and murine tumor models; immune-profiling confirms robust $CD8^+$ T-cell activation and tumor-microenvironment remodeling.

Use of Funds (Seed $3 M)

Finalize lead candidate & CMC readiness
Candidate selection & optimization
01/2026
On track

Complete GLP-toxicology & IND-enabling studies
IND-enabling studies & regulatory package
01/2027
Planned

Engage FDA for early alignment

Advance strategic BD discussions with PD-1 market leaders
Strategic partnership / licensing exit
06/2027
Planned

Business Model

Co-development or royalty-bearing license with PD-1 antibody owners, enabling rapid market entry under existing labels and reimbursement codes.

Investment Ask & Exit

- Raising $3 M Seed funding to reach IND-ready status within 18 months.
- Targeted strategic exit (license, option-to-acquire, or Series A led by strategic) within 24 months, aligning with big-pharma demand for next-gen PD-1 combinations.

SBP